Topotecan

Generic Name
Topotecan
Brand Names
Hycamtin, Potactasol, Topotecan Hospira
Drug Type
Small Molecule
Chemical Formula
C23H23N3O5
CAS Number
123948-87-8
Unique Ingredient Identifier
7M7YKX2N15
Background

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication

用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions
Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Associated Therapies
-
Clinical Trials
Related News

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Phase 3
Completed
Conditions
Small Cell Lung Cancer
Interventions
Drug: Amrubicin
Drug: Topotecan
First Posted Date
2007-10-22
Last Posted Date
2019-11-06
Lead Sponsor
Celgene
Target Recruit Count
637
Registration Number
NCT00547651
Locations
🇺🇸

Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States

🇺🇸

Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States

🇺🇸

Cancer Care Associates of Fresno Medical Group, Inc., Fresno, California, United States

and more 135 locations

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Phase 1
Terminated
Conditions
Ovarian Cancer
Interventions
Drug: Sorafenib
Drug: Topotecan
First Posted Date
2007-09-10
Last Posted Date
2016-03-03
Lead Sponsor
Daniela Matei, MD
Target Recruit Count
30
Registration Number
NCT00526799
Locations
🇺🇸

Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States

🇺🇸

Schwartz Gynecologic Oncology, PLLC, Brightwaters, New York, United States

🇺🇸

Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

and more 5 locations

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

First Posted Date
2007-08-31
Last Posted Date
2013-09-05
Lead Sponsor
University of Chicago
Target Recruit Count
15
Registration Number
NCT00523432
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

First Posted Date
2007-08-15
Last Posted Date
2010-12-08
Lead Sponsor
AstraZeneca
Target Recruit Count
48
Registration Number
NCT00516438
Locations
🇬🇧

Research Site, Manchester, United Kingdom

Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors

First Posted Date
2007-07-18
Last Posted Date
2012-08-01
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
2
Registration Number
NCT00502892
Locations
🇺🇸

U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Topotecan for Irinotecan-Refractory SCLC

First Posted Date
2007-07-18
Last Posted Date
2008-03-12
Lead Sponsor
Gachon University Gil Medical Center
Registration Number
NCT00502762
Locations
🇰🇷

Gachon University Gil Medical Center, Incheon, Korea, Republic of

Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 4
Completed
Conditions
Acute Myeloid Leukemia
First Posted Date
2007-06-20
Last Posted Date
2008-11-18
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
47
Registration Number
NCT00488709
Locations
🇪🇸

Hospital Sant Pau, Barcelona, Spain

🇪🇸

Hospital Ntra. Sra. de Sonsoles, Avila, Spain

🇪🇸

Hosptal Joan XXIII, Tarragona, Spain

and more 13 locations

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

Phase 1
Completed
Conditions
Solid Tumours
Interventions
Drug: Topotecan
First Posted Date
2007-06-07
Last Posted Date
2017-11-13
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
59
Registration Number
NCT00483860
Locations
🇳🇱

GSK Investigational Site, Utrecht, Netherlands

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

Phase 3
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Karenitecin
Drug: Topotecan
First Posted Date
2007-05-23
Last Posted Date
2020-03-12
Lead Sponsor
BioNumerik Pharmaceuticals, Inc.
Target Recruit Count
509
Registration Number
NCT00477282

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

First Posted Date
2007-04-27
Last Posted Date
2015-12-16
Lead Sponsor
HealthPartners Institute
Target Recruit Count
16
Registration Number
NCT00466232
Locations
🇺🇸

Park Nicollet Institute, St. Louis Park, Minnesota, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy